News
WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility
WuXi Biologics, a global company with leading open-access biologics technology platforms, announced that it has received the License of Manufacturing Permit from German health authorities for its drug product facility (DP7) in Leverkusen, Germany. The permit successfully demonstrates for...
News
COVID-19 vaccine Spikevax approved for children aged 12 to 17 in EU
EMA’s human medicines committee (CHMP) has recommended granting an extension of indication for the COVID-19 vaccine Spikevax (previously COVID-19 Vaccine Moderna) to include use in children aged 12 to 17 years. The vaccine is already authorised for use in...
Drug Research
Abzena and BioXpress Therapeutics announce partnership to support the development and manufacture of biosimilars for global customers
Abzena, a Global Partner Research Organization for integrated bench to patient solutions for biologics and bioconjugates, and BioXpress Therapeutics, a world-class leading developer of high quality, monoclonal antibody (mAb) biosimilar therapeutics have announced their partnership to support biosimilar development...
News
Pistoia Alliance Bridges the Gap Between User Experience and Digital Transformation with New Set of Heuristics
The Pistoia Alliance, a global, not-for-profit alliance that advocates for greater collaboration in life sciences R&D, published a set of nine heuristics for user experience (UX) designers. Many life science organizations are undertaking digital transformation initiatives and are handling...
Drug Research
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC Protein Degrader ARV-471
Arvinas, Inc. and Pfizer Inc. announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. ARV-471 is...
News
AstraZeneca’s Vaxzevria is highly effective after one dose against severe disease or hospitalisation caused by Beta and Delta variants of concern
Results from the Canadian Immunization Research Network (CIRN) with support from Public Health Agency of Canada and the Canadian Institutes of Health Research, published as a pre-print, demonstrated one dose of Vaxzevria was 82% effective against hospitalisation or death...
News
Labcorp To Offer First And FDA-Cleared Test For Monitoring Residual Blood Cancer Cells During And After Treatme
Labcorp, a leading global life sciences company, announced that it is now offering clonoSEQ®, the first U.S. Food and Drug Administration (FDA)-cleared test that can identify whether cancer cells remain in a patient’s body during and after treatment for...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















